Matthew Porteus, Kamau Therapeutics co-founder and acting CEO
Graphite founder takes drug to recently-launched Kamau Therapeutics for a second chance: #ASH23
SAN DIEGO — After Graphite Bio’s implosion, Matthew Porteus wants to do things differently.
The Stanford researcher’s stint at the biotech ended with Graphite
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
